SYBX - マイア―ルエヌエイ・セラピュ―ティクス （Synlogic Inc.）

Tempo Automation (TMPO) -15%.NeuroSense Therapeutics (NRSN) -15%.Synlogic (SYBX) -15%.Panbela Therapeutics (PBLA) -16%.Celyad Oncology (CYAD) -11%.Apexigen (APGN) -10%.TC Biopharm…

The following slide deck was published by Synlogic, Inc.

AVYA has seen its SMA50 which is now -66.82%. In looking the SMA 200 we see that the stock has seen a -91.29%. SYBX has seen its SMA50 which is … The post Little Known Factors That Could Affect shares: Avaya Holdings Corp. (NYSE:AVYA -2.61%), Synlogic, Inc. (NASDAQ:SYBX 0.85%) appeared first on Stocks Equity .

The U.S. Food and Drug Administration ((FDA)) granted rare pediatric disease designation ((RPDD)) to Synlogic''s (SYBX) SYNB1934 to potentially treat phenylketonuria ((PKU)).PKU is a…

In last trading session, Synlogic Inc. (NASDAQ:SYBX) saw 0.14 million shares changing hands with its beta currently measuring 1.14. Company’s recent per share price level of $0.62 trading at -$0.02 or -2.36% at ring of the bell on the day assigns it a market valuation of $43.18M. That closing price of SYBX’s stock is at … Synlogic Inc. (NASDAQ:SYBX) Drops -12.93% In One Week: What’s Boosting Its Stock? Read More »

In last trading session, Synlogic Inc. (NASDAQ:SYBX) saw 0.14 million shares changing hands with its beta currently measuring 1.14. Company’s recent per share price level of $0.62 trading at -$0.02 or -2.36% at ring of the bell on the day assigns it a market valuation of $43.18M. That closing price of SYBX’s stock is at … Synlogic Inc. (NASDAQ:SYBX) Drops -12.93% In One Week: What’s Boosting Its Stock? Read More »

Synlogic press release (SYBX): Q3 GAAP EPS of -$0.25 misses by $0.02.Revenue of $0.7M (-22.2% Y/Y) beats by $0.61M.

Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023

Synlogic''s IP is a genetically altered live bacteria that can be engineered to deliver a specific therapeutic effect. Here''s my take on SYBX''s prospects.

The clinical-stage biotech Synlogic, Inc. (SYBX) jumped ~10% on Tuesday after the company reported top-line data from the Phase 2 trial for experimental oral drugs SYNB1934 and SYNB1618…

Synlogic (SYBX) has appointed Michael Jensen as CFO. Mr

Synlogic Inc (SYBX) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $142M. The stock is currently down 15.3% year-to-date, down 14.6% over the past 12 months, and down 85.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 37.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2726.8% The company's stock price performance over the past 12 months beats the peer average by -8.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Brokerages expect Synlogic, Inc. (NASDAQ:SYBX) to announce earnings of ($0.28) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Synlogics earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.24). Synlogic reported earnings of ($0.39) per share in the same quarter []

Synlogic (NASDAQ:SYBX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The companys []